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Abstract
p38γMAPK, one of the four members of p38 mitogen-activated protein kinases (MAPKs), has previously been shown
to harbor oncogenic functions. However, the biologic function of p38γ MAPK in breast cancer has not been well
defined. In this study, we have shown that p38γMAPK is overexpressed in highlymetastatic human andmouse breast
cancer cell lines and p38γMAPK expression is preferentially associated with basal-like and metastatic phenotypes of
breast tumor samples. Ectopic expression of p38γMAPK did not lead to an increase in oncogenic properties in vitro
in most tested mammary epithelial cells. However, knockdown of p38γ MAPK expression resulted in a dramatic
decrease in cell proliferation, colony formation, cell migration, invasion in vitro and significant retardation of tumori-
genesis, and long-distance metastasis to the lungs in vivo. Moreover, knockdown of p38γ MAPK triggered the acti-
vation of AKT signaling. Inhibition of this feedback loop with various PI3K/AKT signaling inhibitors facilitated the effect
of targeting p38γ MAPK. We further found that overexpression of p38γ MAPK did not promote cell resistance to
chemotherapeutic agents doxorubicin and paclitaxel but significantly increased cell resistance to PJ-34, a DNA
damage agent poly (ADP-ribose)-polymerase-1 (PARP) inhibitor in vitro and in vivo. Finally, we identified that p38γ
MAPK overexpression led to marked cell cycle arrest in G2/M phase. Our study for the first time clearly demonstrates
that p38γMAPK is a promising target for the design of targeted therapies for basal-like breast cancer with metastatic
characteristics and for overcoming potential resistance against the PARP inhibitor.
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Introduction
The p38 group of kinases belongs to the mitogen-activated protein
kinase (MAPKs) superfamily and has structural and functional charac-
teristics distinguishable from those of the extracellular signal–regulated
kinase (ERK) and c-JunN-terminal kinases (JNK) [1,2]. There are four
members of the mammalian p38 mitogen-activated protein kinases
(p38α, p38β, p38γ, and p38δ). These MAPKs are approximately 60%
identical in their amino acid sequences but differ in their expression pat-
terns, substrate specificities, and sensitivities to chemical inhibitors [3–7].
All p38 MAPKs are strongly activated in vivo by environmental stresses
and inflammatory cytokines [1,8,9]. However, recent studies indicate that
the physiological functions of different members of the p38 MAPKs may
overlap but not necessarily be identical and/or redundant [10–12].
The distinct biologic role of p38γ (also named MAPK12, ERK6, and
SAPK3) has been explored in recent years. In contrast to p38α, which has
been shown ubiquitously expressed, p38γ is only detectable in certain nor-
mal tissues including skeletal muscle [3,13], and it was also found to be
highly expressed in several human cancer cell lines [14–17]. In addition,
activation of the p38γMAPK cascade—though no other p38 isoforms—
is sufficient to induce G2 arrest in cells. Activation of p38γ is dependent
on ATM and leads to the activation of Cds1 (also known as Chk2). These
data suggest a model in which activation of ATM by γ irradiation leads to
the activation of MKK6, p38γ, and Cds1 and that activation of both
MKK6 and p38γ is essential for the proper regulation of the G2 check-
point in mammalian cells [17]. Particularly, overexpression of Rit, a Ras
family member, in NIH3T3 cells, causes transformation and stimulation
of the expression of p38γ but not other p38MAPKs, ERK1/2, or ERK5
[18]. Consistent with this finding, several studies suggest that the Ras on-
cogene positively regulates the expression of p38γ and depletion of p38γ
suppressed Ras transformation in rat intestinal epithelial cells [16]. Inter-
estingly, p38γ also integrates into the crosstalk between RAS and ER and
increases breast cancer invasion [19]. It has also shown that p38γMAPK
cooperates with c-JUN in transactivating MMP9 [20]. Specifically, p38α
and p38γmediate oncogenic ras-induced senescence through differential
mechanisms [21]. Although the above data strongly indicate the possible
oncogenic role of p38γMAPK in contributing to cellular transformation
and invasive phenotype, the precise functional role of p38γ MAPK in
breast oncogenesis and drug resistance has not been investigated.
In this study, we specifically investigated the expression of p38γ
MAPK in breast cancer cell and tumor samples. We also characterized
the biologic effect of ectopic expression and knockdown expression of
p38γ MAPK on breast cancer cell oncogenic properties including the
cell proliferation, colony formation, cell migration and invasion in vitro,
and tumorigenesis and metastasis in vivo. The effect of p38γMAPK on
cell signaling was also investigated, and a signaling feedback loop caused
by knockdown of p38γMAPK was identified. Finally, we assessed the
significance of p38γ MAPK expression on cell sensitivity to various
drug treatments, including chemotherapeutic agents doxorubicin
(Dox) and paclitaxel (Pac) and the DNAdamage agent poly (ADP-ribose)-
polymerase-1 (PARP) inhibitor PJ-34. Our study represents the first com-
prehensive investigation of the biologic function of p38γMAPK in breast
cancer. The results will facilitate the development of anti–breast cancer
therapeutics based on molecular targeting of p38γMAPK.
Materials and Methods
Cell Cultures
Mouse breast cancer cell lines 4T1, 4T07, 168FARN, and 67 NR
were originally generated by one of the authors (F.R.M.) and have been
characterized for their metastasis capability in vivo [22]. These cells were
cultured in high-glucose Dulbecco modified Eagle medium supple-
mented with 5% fetal bovine serum, 5% newborn calf serum (NCS),
nonessential amino acids (NEAA), and antibiotics (100 U/ml penicillin
and 100 μg/ml streptomycin). All human breast cancer cell lines were
obtained from and characterized by cytogenetic analysis by American
Type Culture Collection (ATCC, Manassas, VA). All these cells were
grown per ATCC recommendations. The mouse mammary epithelial
cell line EpRas and the humanmammary epithelial cell line HMLEwere
obtained from Robert A. Weinberg’s laboratory at Massachusetts Insti-
tute of Technology. EpRas was maintained in Dulbecco modified Eagle
medium, 8% fetal bovine serum, and 500 μg/ml G418. HMLE was
maintained in the culture as described [23]. Both cell lines were authen-
ticated on receipt by comparing them to the original morphologic and
growth characteristics [24].
Expression Constructor, Short Hairpin RNA, and
Lentivirus Generation
A full-length p38γ MAPK plasmid was purchased from Open
Biosystems (Huntsville, AL). A set of short hairpin RNA (shRNA)
clones for p38γ MAPK gene was purchased from Open Biosystems.
The generation of different lentivirus and stable cell lines was accord-
ing to standard procedures [25].
Reverse Transcription–Polymerase Chain Reaction and
Western Blot
Reverse transcription–polymerase chain reaction (RT-PCR) and
Western blot analysis were performed as previously described [25,26].
p38γMAPK polycolony antibody (R&D Systems, Minneapolis, MN)
was used for Western blot analysis.
Transwell Migration and Invasion Assays
Cell migration and invasion assays were performed as before [25,26].
Tissue Microarray and Immunohistochemistry Assay
A breast cancer tissue array, 150 cores including 75 cases of normal,
reactive, premalignant, and malignant tissues of the breast in duplicates,
was purchased from Pantomics (San Francisco, CA). Standard proce-
dures were used for immunohistochemistry assay. The p38γ MAPK
antibody was purchased from Origene (Rockville, MD), and the
working dilution is 1:50.
In Vivo Metastasis Assay
The MCF7-derived tumor cells (1 × 107) in 100 μl of PBS and
Matrigel were injected into the mammary gland of 5-week-old female
NCR nu/nu mice (Taconics, Hudson, NY). The 4T1-derived tumor
cells (2 × 104) in 50 μl of PBS were injected into the mammary gland
of 5-week-old female BALB/C mice (Jackson Laboratory, Bar Harbor,
ME). After tumor cell injections, mice were killed at the fourth week.
The mammary tumor and lungs were removed and embedded into
paraffin blocks. Standard hematoxylin and eosin staining of paraffin-
embedded tissue was performed for histologic examination of metastases.
Chemoresistance Assay, Cell Proliferation, and Colony
Formation Assay
Cells with p38γMAPK overexpression or knockdown and their vec-
tor control were seeded into a 48-well or a 96-well plate (1 × 103 or 5 ×
103 cells/well). After 24 hours, the cells were treated with chemother-
apy agents (Dox and Pac) and PARP inhibitor PJ-34 for 24 hours with
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the indicated doses. After being cultured in a drug-free growth medium
for another 48 hours, the surviving cells were quantified by MTTassay
or clonogenic assay. An MTT assay was performed as described in the
protocol (Promega, Madison, WI) [26]. For the clonogenic assay, the
harvested cells were seeded onto a 10-cm dish. Crystal violet staining
was used to count the colonies after a 10-day culture in growthmedium.
The untreated cells were used to normalize the experimental data.
Cell Cycle Analysis
Cells were seeded in a six-well plate and PJ-34 was added to the cells
after 24 hours. At the indicated times, aliquots of 2 × 105 cells were
washed with PBS and fixed with 70% (vol/vol) ethanol dropwise for
4 hours at −20°C. Cells were washed with PBS, treated with RNAse
A (1 mg/ml) for 30 minutes at 37°C, and stained with propidium
iodide (0.05 mg/ml) for 10 minutes at room temperature. Samples
were analyzed using a FACScan flow cytometer.
Statistical Analysis
A two-sided independent Student’s t test without equal variance
assumption was performed to analyze the results of cell growth, colony
formation, cell migration and invasion, luciferase assay, tumor burdens,
and tumor metastasis. The Cochran-Armitage test was used to analyze
the statistical significant linear trend between the expression of p38γ
MAPK and metastasis phenotypes.
Results
p38γ MAPK Expression Is Associated with Aggressive
Basal-like Breast Cancer and Metastatic Phenotype
in Breast Tumor Samples
To investigate the p38γ MAPK expression pattern in breast cancer,
we first determined the expression of p38γ MAPK in a set of human
breast cancer cell lines with different metastatic capabilities. We found
that a high expression of p38γ MAPK was shown in basal-like and
highly metastatic cancer cell lines, whereas a low expression of p38γ
MAPK was seen in most nonmetastatic or poorly metastatic cell lines
(Figure 1A, top panel ). In addition, we found that p38γ MAPK pro-
tein levels are perfectly consistent with RNA levels, which are higher in
highly metastatic cell lines compared with nonmetastatic or poorly
metastatic cell lines (Figure 1A, low panel ). Moreover, p38γ MAPK
expression was also studied using a panel of mouse model cell lines.
Among these four cell lines, 4T1 is the most highly metastatic cell line
and can metastasize spontaneously from mammary fat pads to the
lungs, liver, and bone (long bones and vertebrae) in most animals.
4T1 also metastasizes to the brain and adrenal gland in some animals,
thus reproducing the pattern found clinically in human breast can-
cer. The three remaining cell lines are nonmetastatic subpopulations
that fail to metastasize at different points in dissemination. 67NR
fails to leave the primary site, 168FARN spreads to the lymph nodes
but travels no further, and 4TO7 cells are routinely recovered from the
Figure 1. Expression of p38γ MAPK in breast cancer cell lines and breast tumor tissues. (A and B) Expression of p38γ MAPK in human
(A) and mouse (B) highly metastatic cell lines. Top panel shows RT-PCR results. Lower panel shows results of Western blot analysis.
(C) Expression of p38γ MAPK is preferentially associated with basal-like breast cancer (P = .006). Group A is basal-like breast tumor
(116 cases); group B is non–basal-like breast tumor (83 cases). (D) IHC assay shows that p38γ MAPK is significantly overexpressed in
the tumor samples with lymph node and distant metastasis (P = .001). Group A (n = 25) includes tumor samples with lymph node and
distant metastasis. Group B (n = 50) includes tumor samples without metastasis and normal tissue.
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lungs but fail to proliferate [22]. The expression level of p38γ MAPK
in mouse model cell lines was found to be concomitant with the meta-
static capability as shown by RT-PCR and Western blot (Figure 1B).
In contrast to p38γMAPK, the expression of three other p38 MAPKs
including p38α, p38β, and p38δ MAPK showed no consistent cor-
relation to basal-like and metastatic phenotype in both human and
mouse breast cancer model cell lines (Figure W1).
We then sought to determine whether the expression of p38γ
MAPK correlates with certain pathologic phenotypes in clinical breast
tumor samples. We analyzed a breast cancer gene expression data set,
which contained 116 basal-like breast tumors and 83 non–basal-like
breast tumors according to their triple-negative status. We found that
the level of p38γ MAPK expression was significantly higher in basal-
like breast tumors than in non–basal-like breast tumors (P = .006) (Fig-
ure 1C). Moreover, we performed an immunohistochemistry (IHC) to
investigate the p38γMAPK expression in breast tumors using a tissue
microarray. The relation of p38γMAPK and pathologic characteristics
was analyzed (Figure W2B). Specifically, we found that high expression
of p38γMAPK is present in 36% of the breast tumors with metastasis
and in only 10% of the breast tumors without metastasis). In contrast, a
low expression of p38γMAPKwas found in only 36% of breast tumors
with metastasis and in 74% of breast tumors without metastasis
(Figures 1D and W2A). The Cochran-Armitage test for trend reveals
that there is a statistically significant linear trend between the expression
of p38γ MAPK gene and metastatic phenotypes (P < .001). Overall,
these results suggest that the high expression of p38γ MAPK is a mo-
lecular occurrence related to the metastatic phenotype and basal-like
characteristics in breast cancer cell lines and tumor samples.
Knockdown of p38γ MAPK Significantly Inhibits Oncogenic
Properties In Vitro and In Vivo
To investigate the function of p38γ MAPK in breast cancer onco-
genic properties, we first established knockdown model cell lines based
on the highly metastatic mouse mammary epithelial cell 4T1, which
also shows the most predominant p38γMAPK expression.When com-
pared with parental 4T1 and 4T1 cells with nontarget control and vec-
tor control, three of five shRNA clones showed more than 80% shut
down of p38γ MAPK expression as evidenced by the Western blot
(Figure 2A). We further observed that inhibition of p38γ MAPK
expression markedly inhibits the cell proliferation and colony forma-
tion (shRNA clone1/nontarget control = 80%, P < .001 and shRNA
clone2/nontarget control = 68%, P < .001) using these stable cell lines
Figure 2. Effect of knockdown of p38γ MAPK on oncogenic properties in vitro. (A) Knockdown of p38γ MAPK expression in 4T1 cells
significantly inhibits cell proliferation. Top panel shows five shRNA clones that differentially inhibit the expression of p38γ MAPK in 4T1
cells. β-Actin is a protein-loading control. Lower panel shows two clones with knockdown of p38γ MAPK expression that have inhibited
cell proliferation compared with parental 4T1 cell and 4T1 with nontarget control in 7 days. (B, C, and D) Knockdown of p38γMAPK expres-
sion in 4T1 cells significantly inhibits colony formation (B), cell migration (C), and invasion (D). Two clones (sh1 and sh2) with knockdown of
p38γMAPK expression and one clone (sh3) without significant p38γMAPK expression changewere used to compare with parental 4T1 cell
and 4T1 with nontarget control.
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(Figures 2A, W3A, and 2B). Moreover, knockdown of p38γ MAPK
expression in 4T1 cells led to a marked decrease in cell migration
(80%, P < .001) (Figures 2C and W3B) and invasion (93.75%, P <
.001) (Figures 2D and W3B).
We then tested the effect of p38γ MAPK knockdown on breast
cancer tumorigenesis and metastasis in vivo using BALB/C mice after
orthotopic injection. Cells with two p38γMAPK knockdown shRNA
clones (shRNA1 and shRNA2) showed significant retardation in tumor
burden in the mammary gland after 28 days compared with cells with
nontarget control, shRNA3 and parental 4T1 cells (Figure 3A). Cells
with the shRNA1 clone showed smaller tumor burden compared to
cells with the shRNA2 clone, suggesting a correlation of p38γ MAPK
expression with tumorigenesis, data consistent with the result of the
in vitro study. Moreover, significantly reduced lung metastasis was also
observed in mice implanted with cells of two p38γMAPK knockdown
shRNA, although cells with nontarget control showed similar quantities
of lung metastasis to parental 4T1 cells (Figure 3, B and C ). Taken
together, these data suggest that a high-level expression of p38γMAPK
is critical for breast cancer cells to maintain their oncogenic properties
in vitro and in vivo.
Ectopic Expression of p38γ MAPK Alone Cannot Promote
Oncogenic Properties In Vitro and In Vivo
To complement the results we obtained above, we generated p38γ
MAPK ectopic expression models based on five different breast cancer
cell lines using a lentivirus system. These cell lines are BT20, MCF7,
HMLE, 67NR, and EpRas, and they all have low or no expression of
p38γ MAPK. We then investigated the effect of p38γMAPK ectopic
expression on oncogenic characteristics. Interestingly, we did not ob-
serve any significant change in cell proliferation, colony formation, cell
migration, and invasion in most of the tested cell lines except MCF7
(Figures 4, W5, W6, W7, and W8). The MCF7 cell line with ectopic
expression of p38γ MAPK had no change in cell proliferation and
Figure 3. Effect of knockdown of p38γMAPK expression in tumorigenesis and distal metastasis in vivo. (A and B) Two clones with knock-
down p38γMAPK expression (p38γ-sh1 and p38γ-sh2) show inhibited tumor burden in vivo (A) and reduced lung metastasis (B) compared
with parental 4T1 cell, 4T1 with nontarget control, and 4T1 cells without significant p38γ MAPK expression change (p38γ-sh3). Ten mice
were used in each group. (C) Representative hematoxylin and eosin staining pictures of lung sections from mice injected with 4T1-derived
cells (magnification, ×100 and ×200). The origin of the lung section is shown on the right of the panels.
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colony formation but had a increase in cell migration (3-folds, P < .001)
and invasion (2.5-folds, P = .031) compared with their vector control
counterparts (Figures 4C and W4, A and B).
To further validate the role of p38γMAPK in oncogenesis, we ortho-
topically injected the MCF7 model cell line with ectopic expression of
p38γMAPK into the fat pads of nude mice and tested for the tumori-
genesis and metastatic propensity. Ectopic expression of p38γMAPK in
MCF7 showed no difference in tumor growth speed and final tumor
burden compared with MCF7 cells with vector control (Figure 4D).
Similarly, no significant difference in lung metastasis was observed in
MCF7 cells with and without p38γ MAPK expression (Figure W4C).
Taken together, these data suggest that overexpression of p38γ MAPK
alone is insufficient to promote tumorigenesis and metastasis.
Knockdown of p38γ MAPK Leads to a Feedback
Signaling Loop
To explore the mechanism underlying p38γ MAPK function, we
checked the common cell signaling pathways related to cell prolifera-
tion, mobility, and cell-to-cell interaction. Western blot results showed
that knockdown of p38γ MAPK in 4T1 significantly decreased ex-
pression of p-ERK. The result of cell signaling is concomitant with
decreased cell proliferation, cell invasion and migration, and retarded
tumorigenesis and inhibited long-distance metastasis. Interestingly,
p-AKT and p-Src expression was significantly increased because of the
knockdown of p38γMAPK (Figure 5A). Conversely, overexpression of
p38γMAPK led to a decrease in p-AKT in bothMCF7 and EpRas cells
and an increase in p-ERK in only EpRas cells (Figure W9).
Figure 4. Effect of ectopic expression of p38γ MAPK on oncogenic properties of MCF7 cells in vitro and in vivo. (A) Ectopic expression
of p38γMAPK in MCF7 cells has no effect on cell proliferation. The top panel shows ectopic expression of p38γMAPK in MCF7 cells. V5
antibody is used to detect p38γMAPK. β-actin is a protein loading control. The lower panel shows cell proliferation ofMCF7 cells expressing
vector control and p38γ MAPK gene in 11 days. (B) Ectopic expression of p38γ MAPK in MCF7 cells does not lead to change in colony
formation compared with MCF7 cells with vector control. (C) Ectopic expression of p38γ MAPK in MCF7 cells leads to an increase in cell
migration (top panel) and cell invasion (low panel) compared with MCF7 cells with vector control. (D) Effect of ectopic expression of p38γ
MAPK on tumorigenesis. The cells with ectopic p38γ MAPK expression show no significant difference in tumor burden in vivo compared
with parental MCF7 cell with vector control. Eight mice were used in each group.
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Figure 5. Effect of p38γ MAPK on cell signaling pathways. (A) Effect of p38γ MAPK on AKT and ERK signaling by Western blot analysis
assay. Western blots show the changes in cell signaling when p38γ MAPK is knocked down in 4T1 cells. (B, D, and F) The effect of
combination of knockdown of p38γMAPK and various AKT signaling inhibitors on cell proliferation with different time courses. The right
panels show the final comparison of the cell survival rate between nontarget clone and knockdown clone after treatment of different
inhibitors. (C, E, and G) Effect of the combination of knockdown of p38γMAPK and various AKT signaling inhibitors on colony formation
with different doses. 4T1 cells with p38γ MAPK knockdown (MK) and nontarget clone (NT) were treated with AKT inhibitor (AKti-1/2)
(B and C), PI3K inhibitor (LY294002) (D and E), and Src inhibitor (Dasatinib) (F and G).
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To further confirm the existence of a signaling feedback loop, we ex-
amined whether specific AKTsignaling inhibitors can sensitize the effects
of targeting p38γ in model cells. Our data clearly showed that for 4T1
cells with p38γ MAPK knockdown, the 1 μM AKT inhibitor signifi-
cantly decreased cell proliferation (Figure 5B). We also showed that the
0.5 and 1 μMAKT inhibitor significantly decreased colony formation in
4T1 cells with p38γMAPK knockdown compared with 4T1 cells with
vector control (Figure 5C). Similarly, two different doses of the specific
PI3K inhibitor LY294002 (3 and 10 μM) and the Src inhibitor (25 and
50 μM) significantly inhibited the cell proliferation and colony formation
in 4T1/p38γ-sh1 cells compared with 4T1 vector cells (Figure 5, D-G).
p38γ MAPK Mediates Cell Sensitivity to the PARP Inhibitor
but Not to Two Conventional Chemotherapeutic Agents
To investigate whether mammary epithelial cells with p38γ MAPK
expression acquire chemoresistant properties like many tumorigenic
and metastatic contributors such as Snail, twist, and MTDH/AEG-1
[27–29], two conventional chemotherapeutic agents Dox and Pac were
Figure 6. Effects of Dox and Pac on 67NR and MCF7 cells with or without p38γ MAPK overexpression. (A and D) Overexpression of p38γ
MAPK in 67NR (A) andMCF7 (D) cells hasnoeffect on the cell proliferationunder the treatmentswithDox andPac. (B and E)Overexpression of
p38γMAPK in 67NR (B) and MCF7 (E) cells has no effect on the colony formation capability under the treatments with Dox. (C and F) Over-
expression of p38γMAPK in 67NR (C) and MCF7 (F) cells has no effect to the colony formation capability under the treatments with Pac.
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used to treat several stable cell lines we established. As measured by
MTT assay, we did not observe any changes in survival cell number
in 67NR, MCF7, HMLE, and BT20 cells when treated with different
doses of Dox and Pac (Figures 6, W10, W11, and W12). This result
was also confirmed by the unchanged survival colony numbers mea-
sured with the clonogenic assay. In addition, Dox and Pac treatment
in 4T1 cells with p38γ MAPK knockdown did not show any effect
compared with 4T1 cells with vector control (data not shown). These
data suggest that p38γ MAPK expression does not contribute to the
resistance of regular chemotherapeutic agents in breast cancer cell lines.
We next studied whether the expression of p38γMAPK contributes
to cells’ resistance of the PARP inhibitor, a recently developed thera-
peutic approach for cancer with BRCA mutation and basal-like breast
cancer [30–32]. 67NR cells with ectopic expression of p38γ MAPK
Figure 7. Effect of ectopic expression of p38γMAPKon cell resistance to the PARP inhibitor. (A and B) The 67NR cells (A) and HMLE cells (B)
with ectopic expression of p38γMAPK show significant resistance to PARP inhibitor PJ-34. The left panel shows the cell proliferation after
PJ-34 treatment. The right panel shows the quantification of the clonogenic assay results. Different doses of PJ-34 are shown. (C) Effect
of p38γ MAPK and PJ-34 treatment on tumorigenesis in vivo. Relative final tumor weights were shown after PJ-34 was used for 16 days.
(D) Ectopic expression p38γMAPK and PJ-34 treatment led to G2/M arrest in 67NR cells. 67NR cells with LacZ and p38γMAPK expression
were treated with DMSO (Untreated) and 15 μM PJ-34 for 2 days. Cell cycle was measured by flow cytometry assay.
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and its vector control counterpart were treated with three different doses
of PARP inhibitor PJ-34. We observed that significant cell survival and
colony survival in 67NR cells with p38γ MAPK expression occurred
compared with vector control cells (Figures 7A and W13). In addition,
when HMLE-derived cells were treated with different doses of PJ-34,
we also observed that HMLE cells with p38γ MAPK expression have
significant survival rates compared with HMLE cells with vector control
(Figures 7B andW14A). Similar results were also obtained whenMCF7
cells were treated with different doses of PJ-34 (Figure W14B). More-
over, PJ-34 treatment on 4T1 cells with p38γ MAPK knockdown
showed inhibitory effects on cell proliferation in a concentration higher
than 15 μM (Figure W15A). The inhibitory effects of knockdown of
p38γMAPK and PJ-34 treatment were observed at a lower concentra-
tion at 2.5 μM when AKT inhibitor is added (Figure W15B). These
data further confirmed the existence of the feed back loop of survival
signaling. Furthermore, 67NR cells with ectopic expression of p38γ
MAPK and its vector control counterpart were subcutaneously injected
into nude mice. Without drug treatment, the 67NR cells with ectopic
expression of p38γ MAPK and its vector control grew at equal rates.
However, with the PJ-34 treatment, the tumor burden in 67NR cells
with vector control group significantly shrank approximately 40% com-
pared with untreated 67NR cells with vector control (P = .009). Sig-
nificance was also observed when vector control group was compared
with the p38γMAPK expression group at day 16 after PJ-34 treatment
(Figure 7C , P = .03).
Finally, we investigated the effect of p38γ MAPK on cell cycle. Ec-
topic expression of p38γ MAPK in 67NR cells induced clear G2/M
arrest (threefolds, 38.6%/12.42%). The G2/M arrest was markedly
enhanced when 67NR cells with p38γ expression were treated with
PJ-34 (Figure 7D, 48.76%/38.63%). In contrast, no significant increase
of G2/M arrest was observed when the control 67NR cells were treated
with PJ-34 (13.54%/12.42%), suggesting that p38γ MAPK over-
expression is important to cell cycle arrest, and it can be the mechanism
of breast cancer cells to survival in the DNA-damaging conditions.
Discussion
The results of our current study show specific overexpression of p38γ
MAPK in basal-like breast cancer cell lines and tumor samples and
correlate with the metastatic potential in breast tumor samples. These
data are in agreement with several previous reports that indicated the
potential oncogenic role of p38γ MAPK in cancer progression. How-
ever, a functional study showed that ectopic expression of p38γMAPK
in several breast cancer cell lines did not lead to significant changes in
oncogenic characteristics. Conversely, knockdown of p38γ MAPK re-
sulted in the significant diminution of the oncogenic characteristics of
breast cancer cells, suggesting that the main function of p38γ MAPK
in breast cancer is to maintain the oncogenic properties rather than to
promote cancer progression. Other genetic alterations are needed to
cooperate with p38γ MAPK to ensure complete tumorigenesis and
metastasis of breast cancer cells.
Using the ectopic and knockdown model cell lines, our results dem-
onstrated that p38γMAPK is involved in the Ras/ERK signaling path-
way in breast cancer. One interesting finding of the current study is that
knockdown of p38γMAPK in breast cancer cells led to the activation
of the AKT signaling pathway, indicating the existence of a signaling
feedback loop. From the therapeutic point of view, the signaling feed-
back loop is one reason of therapeutic resistance. Targeting the potential
signaling feed back loop could significantly improve therapeutic efficacy
[25,33–35]. Indeed, significant effects were observed when we treated
p38γ MAPK knockdown breast cancer cells with various inhibitors
targeting AKT signaling pathway. These data are supported by a report
that shows that the combination of PI3K and MEK inhibitors confers
high effectiveness in murine models of lung cancers that expressed mu-
tant K-ras [36]. Moreover, the existence of the signaling feedback loop
also conceals the effect of other therapeutic drugs such as PJ-34 (Fig-
ureW15). Taken together, the results of our study suggest that concomi-
tant inhibition of AKT signaling with specific targeting p38γ MAPK
could be a much more effective approach than only targeting p38γ
MAPK in breast cancer treatment.
It has been shown that cells deficient in DNA DSB repair, in particu-
lar homologous recombination (HR) by gene conversion, are highly
sensitive to chemical inhibitions of PARP [30,31,37]. Conversely, the
breast and ovarian cancer predisposition genes, BRCA1 and BRCA2,
encode proteins that are required for efficient HR [38,39]. Therefore,
PARP inhibitor treatment could be an effective approach to target
cancers with BRCA1 and BRCA2 mutations, which are HR-defective.
Moreover, basal-like or triple-negative breast cancers have features that
mimic those of tumors arising in BRCA1 mutation carriers. Most pa-
tients with BRCA1 germ line mutations develop basal-like or triple-
negative breast cancers [40–42]. This overlap suggests that part of the
basal-like or triple-negative breast cancers, for which targeted therapy is
unavailable, may respond to therapeutics targeting BRCA1-deficient
cells [43]. Our current study showed that p38γ MAPK up-regulation
induced a significant resistance to PARP inhibitor treatment in breast
cancer cell lines. These data are consistent with a previous report that
shows that p38γ MAPK is one of the six genes mediating sensitivity
to the PARP inhibitor by a synthetic lethal small interfering RNA screen
[44]. Moreover, ectopic expression of p38γ MAPK could lead to sig-
nificant cell cycle arrest in the G2/M phase. Taken together, our data
indicate that the p38γMAPK is a negative mediator of the cellular sen-
sitivity to DNA damage in breast cancer. Targeting p38γMAPK along
with PARP treatment could increase the therapeutic efficacy in the basal-
like breast cancer population.
In summary, our study for the first time provides solid biologic
evidences implicating p38γMAPK as a critical molecule for maintain-
ing oncogenic properties and contributing to specific resistance to
the PARP inhibitor in basal-like breast cancer. Future studies that will
include the design of specific p38γ MAPK inhibitor, the generation
of transgenic or knockout mice, and the further exploration of the
mechanism underlying p38γ MAPK are needed to eventually estab-
lish the role of p38γ MAPK as a therapeutic candidate for of breast
cancer treatment.
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Figure W1. The expression pattern of different p38 MAPKs in breast cancer cell lines. (A) Expression of p38α, p38β, and p38δ MAPK in
a panel of human breast cancer cell lines. “+” stands for highly metastatic cell lines. “−” stands for poorly metastatic cell lines. GAPDH is
an RNA loading control. (B) Expression of p38α, p38β, and p38δMAPK in a panel of mouse breast cancer cell lines. Triangular bar indicates
the increase of metastasis capability. GAPDH is an RNA loading control.
Figure W2. IHC results in a tissue microarray. (A) Representative IHC staining figure for breast tumor samples with lymph node and
distant metastasis. (B) Statistical analysis of the relation of p38γ expression and different pathologic characteristics of breast tumor
samples; five normal samples were excluded from these analyses.
Figure W3. Effect of knockdown of p38γ MAPK on cell proliferation, migration, and invasion in vitro. (A) Comparison of effect of different
cell numbers on cell proliferation. Cells (2000 cells/well [left panel] and 1000 cells/well [right panel]) were seeded in 96-well plates and
MTT assays were tested. (B) Representative figures show the migration (top) and invasion (bottom) abilities of 4T1 parental cells, 4T1 cells
transfected with nontarget vector, and three shRNA clones.
Figure W4. Effect of ectopic expression of p38γMAPK on migration, invasion, and metastasis in MCF7 cells. (A) Representative figures
for the migration assay using MCF7/LacZ and MCF7/p38γ MAPK cells. (B) Representative figures for the invasion assay using MCF7/
LacZ and MCF7/p38γMAPK cells. (C) Representative figure for the lung section from the mice xenografted with MCF7/LacZ and MCF7/
p38γ MAPK cells. No significant metastasis was observed in both xenograft models.
Figure W5. The effect of overexpression of p38γ MAPK on cell proliferation, colony formation, migration, and invasion in HMLE cells.
(A) Top panel confirmed the expression of p38γ MAPK in HMLE cells. MTT assay shows no changes of cell proliferation when p38γ
MAPK was overexpressed in HMLE cells (lower panel). (B) Colony formation assay shows that overexpression of p38γ MAPK in HMLE
cells does not change the colony formation capability of HMLE cells (P = .67). (C and D) Overexpression of p38γ MAPK in HMLE cells
does not affect cell migration (C; P = .14) and invasion (D; P = .53) capabilities.
Figure W6. Effect of overexpression of p38γMAPK on cell proliferation, colony formation, migration, and invasion in BT20 cells. (A) Top
panel shows the ectopic expression of p38γ MAPK in BT20 cells. MTT assay shows no changes of cell proliferation when p38γ MAPK
was overexpressed in BT20 cells (lower panel). (B) Colony formation assay shows that overexpression of p38γMAPK in BT20 cells does
not change the colony formation capability of BT20 cells (P= .92). (C and D) Overexpression of p38γMAPK in BT20 cells does not affect
cell migration (C; P = .90) and invasion (D; P = .66) capabilities.
Figure W7. Effect of overexpression of p38γ MAPK on cell proliferation, colony formation, migration and invasion in 67NR cells. (A) Top
panel shows the ectopic expression of p38γMAPK in 67NR cells. MTT assay shows no changes in cell proliferation when p38γMAPK was
overexpressed in 67NR cells. (B) Colony formation assay shows that overexpression of p38γ MAPK in 67NR cells does not change the
colony formation capability of 67NR cells (P = .96). (C and D) Overexpression of p38γ MAPK in 67NR cells does not affect cell migration
(C; P = .59) and invasion (D; P = .50) capabilities.
Figure W8. Effects of overexpression of p38γMAPK on cell proliferation, colony formation, and invasion in EpRas cells. (A) Top panel shows
ectopic expression of p38γMAPK in EpRas cells. MTT assay shows no changes of cell proliferation when p38γMAPKwas overexpressed in
EpRas cells (lower panel). (B) Colony formation assay shows that overexpression of p38γMAPK in EpRas cells does not change the colony
formation capability of EpRas cells (P = .65). (C and D) Overexpression of p38γMAPK in EpRas cells does not affect cell migration (C; P =
.40) and invasion (D; P = .71) capabilities.
Figure W9. Effect of p38γMAPK on cell signaling pathways in p38γ
MAPKoverexpressed cells. (A) Effect of p38γMAPKonAKT and ERK
signaling in EpRas cells. (B) Effect of p38γ MAPK on AKT and ERK
signaling in MCF7 cells.
Figure W10. Effects of p38γ MAPK overexpression on chemoresistance in 67NR cells and MCF7 cells. (A and B) Representative colony
formation plates showing the effect of treatment of different doses of two chemotherapeutic agents Dox and Pac on 67NR cells. (C and D)
Representative colony formation plates showing the effect of treatment of different doses of two chemotherapeutic agents Dox and Pac
on MCF7 cells.
Figure W11. Effects of Dox and Pac on HMLE cells with or without p38γMAPK overexpression. (A) Overexpression of p38γMAPK in HMLE
cells has no effect on the cell proliferation under the treatments with Dox. (B) Overexpression of p38γMAPK in HMLE cells has no effect on
the cell proliferation under the treatments with Pac. (C) Overexpression of p38γMAPK in HMLE cells has no effect on the colony formation
capability under the treatments with Dox. (D) Overexpression of p38γMAPK in HMLE cells has no effect to the colony formation capability
under the treatments with Pac.
Figure W12. Effects of Dox and Pac on BT20 cells with or without p38γ MAPK overexpression. (A) Overexpression of p38γ MAPK in
BT20 cells has no effect on the cell proliferation under the treatments with Dox and Pac. (B) Overexpression of p38γMAPK in BT20 cells
has no effect on the colony formation capability under the treatments with different doses of Dox and Pac. Top panel shows the relative
survival colonies. Lower panels show the representative plates of colony formation.
Figure W13. Effects of PJ-34 treatment on 67NR cells with or without p38γ MAPK overexpression. (A) Representative figures for the
clonogenic assay for HMLE/Lac/Z and HMLE/p38γ MAPK treated with PJ-34. (B) Morphologic change of the 67NR cells when treated
with different doses of PJ-34.
Figure W14. Effects of PJ-34 on HMLE (A) and MCF7 cells (B) with or without p38γ MAPK overexpression. (A) Representative figures for
the colongenic assay for HMLE/Lac/Z and HMLE/p38γMAPK treated with PJ34. (B) Overexpression of p38γMAPK in MCF7 cells increases
the resistance to PJ-34 in colony formation assays. Top panel shows the summary of the results from three independent assays. Lower
panel shows the representative figures.
Figure W15. Effects of PJ-34 treatment and AKT inhibitor on in 4T1 cells with p38γ MAPK knockdown. (A) Survival cell number is signifi-
cantly decreased in 4T1 cells with p38γ MAPK knockdown when the PJ-34 concentration is higher than 15 μm. (B) With the AKT inhibitor
VIII (AKT-1/2, 1 μm), the survival cell number is significantly decreased in 4T1 cells with p38γ MAPK knockdown when the PJ-34 con-
centration is 2.5 μm.
